Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stem cells from human exfoliated deciduous teeth (SHED) are a population of mesenchymal stem cells (MSCs) derived from the dental pulp of naturally shed primary teeth. They are characterized by high proliferative capacity, multi-lineage differentiation potential (including odontogenic, osteogenic, and neurogenic), and potent immunomodulatory properties. In clinical applications, SHED are being investigated for dental pulp regeneration in permanent teeth with pulp necrosis. The therapy involves the implantation of allogeneic SHED into the root canal to promote the formation of new vascularized pulp-like tissue and restore sensory function, offering a regenerative alternative to conventional root canal therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on stem cells from human exfoliated deciduous teeth.